Inflammation as a new target in CV risk reduction - PACE-CME

Inflammation as a new target in CV risk reduction

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Predicting 30-year CV outcomes in women
Predicting 30-year CV outcomes in women
ESC Congress 2024
Predicting 30-year CV outcomes in women
- Paul Ridker, MD
Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
The role of inflammation in atherosclerosis
The role of inflammation in atherosclerosis
Inflammation
The role of inflammation in atherosclerosis
- Peter Libby, MD
Ongoing benefit with bempedoic acid in reducing total incidence of MACE
Ongoing benefit with bempedoic acid in reducing total incidence of MACE
ESC Congress 2023
Ongoing benefit with bempedoic acid in reducing total incidence of MACE
- Stephen Nicholls, MD